ArticleObesity surgery2014
Roux-en-Y esophagojejunostomy reduces serum and aortic inflammatory biomarkers in type 2 diabetic rats.
Article in Obesity surgery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Roux-en-Y Esophagojejunostomy Ameliorates Renal Function Through Reduction of Renal Inflammatory and Fibrotic Markers in Diabetic Nephropathy.Obesity surgery · 2016Article
- Catalpol ameliorates diabetic atherosclerosis in diabetic rabbits.American journal of translational research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent studies have shown the reduction in serum inflammatory biomarkers by bariatric surgery. However, few studies have reported its effects on local vascular inflammation. We have investigated the effects of Roux-en-Y esophagojejunostomy on both serum and aortic tissue inflammation biomarkers in type 2 diabetic rats.
methodsSprague-Dawley rats were divided into five groups: diabetic RYEJ, diabetic RYEJ sham, diabetic food restriction, diabetic rats, and non-diabetic control (n = 6/group). At 4 weeks after surgery, serum leptin, interleukin-6, C-reactive protein, interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), chemerin, and adiponectin were measured. Aortic expression of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinases was examined with immunohistochemistry; aortic expression of IL-1β, TNF-α, intercellular adhesion molecule-1, and vascular adhesion molecule-1 was assessed with western blotting. Hyperinsulinemic-euglycemic clamps with tracer infusion were completed to assess insulin sensitivity.
resultsRoux-en-Y esophagojejunostomy significantly decreased serum inflammatory parameters and increased the concentration of the anti-inflammatory mediator adiponectin. The aortic inflammatory protein expression was markedly decreased in the diabetic RYEJ group as compared with that of the diabetic group (P < 0.05). Additionally, Roux-en-Y esophagojejunostomy improved insulin sensitivity and dyslipidemia and decreased body weight and total body fat.
conclusionsRoux-en-Y esophagojejunostomy reduces the systemic and local vascular inflammation. The improvements in systemic and vascular inflammation are not wholly dependent on the magnitude of weight loss. Moreover, Roux-en-Y esophagojejunostomy alleviates insulin resistance and improves the features of metabolic syndrome, leading to a reduction in multiple cardiovascular risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.